BPC-157 and TB-500 are both prohibited for compounding in the US and have no FDA approval. They are marketed for tissue repair and recovery, with animal data but no completed human trials. Neither is a legal option for human use through US pharmacies.
Comparing Epithalon and Vilon: both have distinct mechanisms, FDA status, and use cases. Read the sections below to decide which may be right for you.
GHK-Cu is compoundable for topical use only (Category 1); it is a legal option for skin and wound support. BPC-157 is prohibited for compounding and has no FDA approval—it is not a legal option in the US. For legal tissue and skin support, GHK-Cu (topical) is the only one you can use.
Ipamorelin is prohibited for compounding with no pathway. GHRP-2 has complex status—Category 1 on 503B for non-injectable, non-nasal routes only; injectable use is not permitted. For legal injectable GH support, neither is a clear option; sermorelin is the compoundable choice.
PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is safe when used as directed. Melanotan II is not FDA-approved, has no legal pathway, and carries significant safety concerns including nausea, flushing, and potential melanoma risk. Do not use Melanot
Tirzepatide is the practical choice today: it is a dual GIP/GLP-1 agonist that is FDA-approved (Mounjaro for type 2 diabetes, Zepbound for obesity) and available by prescription now. Retatrutide is a triple GLP-1/GIP/glucagon agonist that produced higher weight loss in its Phase 2 trials (~24% at 48
Semaglutide and liraglutide are both FDA-approved GLP-1 agonists for diabetes and weight loss. Semaglutide is usually given once weekly (or daily oral with Rybelsus) and tends to produce greater weight loss in trials; liraglutide is daily injection and remains a proven, effective option.
Tirzepatide is a dual GIP/GLP-1 agonist and often produces slightly greater weight loss than semaglutide (GLP-1 only) in trials. Both are FDA-approved for type 2 diabetes and obesity. Choice depends on access, cost, and tolerability—many patients do very well on either.
Semax and Selank are both Russian-origin peptides with moderate evidence from Russian studies. Neither is FDA-approved in the US; Semax has no clear compounding pathway, and Selank’s Category 2 nomination was withdrawn. Both are used for cognitive and mood support abroad but are not legal, approved
Sermorelin is legal to compound (Category 1) and was previously FDA-approved; it is a safe, legal option for growth hormone support. CJC-1295/Ipamorelin combination is not legally compoundable—both components are prohibited—and CJC-1295 has been flagged by the FDA for cardiac risks. For legal GH sup